Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 174

1.
2.

Early treated HIV-1 positive individuals demonstrate similar restriction factor expression profile as long-term non-progressors.

Van Hecke C, Trypsteen W, Malatinkova E, De Spiegelaere W, Vervisch K, Rutsaert S, Kinloch-de Loes S, Sips M, Vandekerckhove L.

EBioMedicine. 2019 Mar;41:443-454. doi: 10.1016/j.ebiom.2019.02.006. Epub 2019 Feb 12. No abstract available.

3.

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA.

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D'Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A; EuroSIDA study group.

HIV Med. 2019 Apr;20(4):264-273. doi: 10.1111/hiv.12711. Epub 2019 Feb 8.

PMID:
30734998
4.

In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients.

Pannus P, Adams P, Willems E, Heyndrickx L, Florence E, Rutsaert S, De Spiegelaere W, Vandekerckhove L, Seguin-Devaux C, Vanham G.

AIDS. 2019 Mar 1;33(3):387-398. doi: 10.1097/QAD.0000000000002068.

PMID:
30702513
5.

Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen: a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from ART-suppressed HIV-infected individuals.

Moron-Lopez S, Navarro J, Jimenez M, Rutsaert S, Urrea V, Puertas MC, Torrella A, Clercq L, Ribas BP, Gálvez C, Salgado M, Vandekerckhove L, Blanco J, Crespo M, Martinez-Picado J.

Clin Infect Dis. 2018 Dec 24. doi: 10.1093/cid/ciy1095. [Epub ahead of print]

PMID:
30590412
6.

Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction.

Tulkens J, Vergauwen G, Van Deun J, Geeurickx E, Dhondt B, Lippens L, De Scheerder MA, Miinalainen I, Rappu P, De Geest BG, Vandecasteele K, Laukens D, Vandekerckhove L, Denys H, Vandesompele J, De Wever O, Hendrix A.

Gut. 2018 Dec 5. pii: gutjnl-2018-317726. doi: 10.1136/gutjnl-2018-317726. [Epub ahead of print] No abstract available.

7.

In-depth validation of total HIV-1 DNA assays for quantification of various HIV-1 subtypes.

Rutsaert S, De Spiegelaere W, Van Hecke C, De Scheerder MA, Kiselinova M, Vervisch K, Trypsteen W, Vandekerckhove L.

Sci Rep. 2018 Nov 22;8(1):17274. doi: 10.1038/s41598-018-35403-6.

8.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team.

Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum in: Lancet. 2018 Nov 28;:.

PMID:
30420123
9.

Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy.

Wijting I, Rutsaert SL, Rokx C, Burger DM, Verbon A, van Kampen J, Boucher C, Rijnders B, Vandekerckhove L.

HIV Med. 2019 Jan;20(1):63-68. doi: 10.1111/hiv.12675. Epub 2018 Sep 30.

PMID:
30270543
10.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group .

Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505.

PMID:
29912307
11.

Evaluation of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA recovery using digital PCR.

Kint S, De Spiegelaere W, De Kesel J, Vandekerckhove L, Van Criekinge W.

PLoS One. 2018 Jun 14;13(6):e0199091. doi: 10.1371/journal.pone.0199091. eCollection 2018.

12.

Diabetes-Induced Cardiomyocyte Passive Stiffening Is Caused by Impaired Insulin-Dependent Titin Modification and Can Be Modulated by Neuregulin-1.

Hopf AE, Andresen C, Kötter S, Isić M, Ulrich K, Sahin S, Bongardt S, Röll W, Drove F, Scheerer N, Vandekerckhove L, De Keulenaer GW, Hamdani N, Linke WA, Krüger M.

Circ Res. 2018 Jul 20;123(3):342-355. doi: 10.1161/CIRCRESAHA.117.312166. Epub 2018 May 14.

PMID:
29760016
13.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

De Wit S, Florence E, Vandekerckhove L, Vandercam B, Goffard JC, Van Wijngaerden E, Moutschen M, Demeester R, Thilakarathne P, Piryns H; BREACH* Consortium.

Acta Clin Belg. 2018 Oct;73(5):341-347. doi: 10.1080/17843286.2018.1458428. Epub 2018 Apr 6.

14.

Highlights from the HIV Cure and Reservoir Symposium, 11-12 September 2017, Ghent, Belgium.

Kint S, Van Hecke C, Cole B, Vandekerckhove L, Sips M.

J Virus Erad. 2018 Jan 1;4(1):55-58.

15.

Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25083.

16.

Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe.

Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren JD; EuroSIDA study group.

HIV Med. 2018 May;19(5):324-338. doi: 10.1111/hiv.12581. Epub 2018 Feb 1.

PMID:
29388732
17.

Digital PCR as a tool to measure HIV persistence.

Rutsaert S, Bosman K, Trypsteen W, Nijhuis M, Vandekerckhove L.

Retrovirology. 2018 Jan 30;15(1):16. doi: 10.1186/s12977-018-0399-0. Review.

18.

Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.

Molina JM, Grund B, Gordin F, Williams I, Schechter M, Losso M, Law M, Ekong E, Mwelase N, Skoutelis A, Wiselka MJ, Vandekerckhove L, Benfield T, Munroe D, Lundgren JD, Neaton JD; INSIGHT START study group.

Lancet HIV. 2018 Apr;5(4):e172-e180. doi: 10.1016/S2352-3018(18)30003-1. Epub 2018 Jan 16.

PMID:
29352723
19.

Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.

Fun A, Leitner T, Vandekerckhove L, Däumer M, Thielen A, Buchholz B, Hoepelman AIM, Gisolf EH, Schipper PJ, Wensing AMJ, Nijhuis M.

Retrovirology. 2018 Jan 5;15(1):1. doi: 10.1186/s12977-017-0384-z.

20.

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.

Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A, Fätkenheuer G, Gatell Artigas JM, Karpov I, Kuznetsova A, Kyselyova G, Mozer-Lisewska I, Mulcahy F, Ragone L, Scherrer A, Uzdaviniene V, Vandekerckhove L, Vannappagari V, Ostergaard L, Mocroft A; EuroSIDA study.

HIV Med. 2018 Apr;19(4):252-260. doi: 10.1111/hiv.12573. Epub 2017 Dec 22.

PMID:
29271606

Supplemental Content

Loading ...
Support Center